Medical Therapy. Pharmacokinetics and Pharmacology Archives - Page 2 of 3

Direct prostacyclin transition in pediatric patients with pulmonary hypertension

Kelly Merrill, Anne Davis, Emma Jackson, Meredith Riker, Christa Kirk, Delphine YungSeattle Children’s Hospital and University of Washington School of Medicine.United States Pulmonary CirculationPulm Circ 2024; 14: DOI: 10.1002/pul2.12373 AbstractPediatric patients with pulmonary arterial hypertension (PAH) are commonly treated with the prostacyclin analog treprostinil in IV, SQ, inhaled or oral form, or the prostacyclin receptor agonist […]

Direct prostacyclin transition in pediatric patients with pulmonary hypertension Read More »

Tailoring of Bilosomal Nanogel for Augmenting the Off-Label Use of Sildenafil Citrate in Pediatric Pulmonary Hypertension

Bjad K. Almutairy, El-Sayed Khafagy, Mohammed F. Aldawsari, Abdullah Alshetaili, Hadil Faris Alotaibi, Amr Selim Abu LilaPrince Sattam Bin Abdulaziz University. Suez Canal University. Princess Nourah Bint AbdulRahman University. Zagazig University. University of Hail.Saudi Arabia and Egypt American Chemical Society OmegaACS Omega 2024; 9: 19536-19547DOI: 10.1021/acsomega.4c01133 AbstractPediatric pulmonary hypertension is a serious syndrome with significant morbidity

Tailoring of Bilosomal Nanogel for Augmenting the Off-Label Use of Sildenafil Citrate in Pediatric Pulmonary Hypertension Read More »

Low global arginine bioavailability: a common phenomenon in pulmonary hypertension

Dunia Hatabah, Teresa De Marco, Dana P. McGlothlin, Mary Malloy, Loretta Z. Reyes, Rawan Korman, Gregory J. Kato, Claudia R. MorrisEmory University School of Medicine. University of California, San Francisco. Kaiser Permanente San Francisco. Children’s Healthcare of Atlanta. Blood Science Consulting.United States American Journal of Physiology Lung Cellular and Molecular PhysiologyAm J Physiol Lung Cell

Low global arginine bioavailability: a common phenomenon in pulmonary hypertension Read More »

[Risks of magistral preparations in pediatrics]

Charlotte Rosen, Caroline Jacqmart, Corinne Charlier, Maurice Beghetti, Marie-Christine SeghayeCentre Hospitalier Universitaire de Liège. Hôpitaux universitaires de Genève.Belgium and Switzerland Revue Medicale de LiegeRev Med Liege 2024; 79: 104-109DOI: Not Available AbstractVasoreactive pulmonary arterial hypertension (PAH) in children is a form of idiopathic PAH that responds to vasoreactive testing with nitric oxide (NO) by a

[Risks of magistral preparations in pediatrics] Read More »

Multi-dose enteral L-citrulline administration in premature infants at risk of developing pulmonary hypertension associated with bronchopulmonary dysplasia

Candice D. Fike, Judy L. Aschner, Charul Avachat, Angela K. Birnbaum, Catherine M. T. SherwinUniversity of Utah Health. Albert Einstein College of Medicine. Hackensack Meridian School of Medicine. University of Minnesota. Wright State University Boonshoft School of Medicine.United States Journal of PerinatologyJ Perinatol 2023; DOI: 10.1038/s41372-023-01809-y AbstractObjective: Information is needed to guide the design of randomized controlled

Multi-dose enteral L-citrulline administration in premature infants at risk of developing pulmonary hypertension associated with bronchopulmonary dysplasia Read More »

Serum Levels After Everolimus-Stent Implantation and Paclitaxel-Balloon Angioplasty in an Infant with Recurrent Pulmonary Vein Obstruction After Repaired Total Anomalous Pulmonary Venous Connection

Matthias J. Muller, Ulrich Krause, Thomas Paul, Heike E. SchneiderGeorg-August-University Göttingen.Germany Pediatric CardiologyPediatr Cardiol 2011; 32: 1036-1039DOI: 10.1007/s00246-011-0054-1 AbstractEverolimus-eluting stents and paclitaxel-coated balloons are used in the interventional treatment of coronary artery disease in adults to reduce the restenosis rate and in small-vessel disease. Both substances are released into the circulation. We report systemic drug exposure

Serum Levels After Everolimus-Stent Implantation and Paclitaxel-Balloon Angioplasty in an Infant with Recurrent Pulmonary Vein Obstruction After Repaired Total Anomalous Pulmonary Venous Connection Read More »

The Anti-Inflammatory Effects and Clinical Potential of Dexmedetomidine in Pulmonary Arterial Hypertension

Yohei Yamaguchi, Susumu Hosokawa, Go Haraguchi, Yusuke Kajikawa, Makito Sakurai, Taku Ishii, Noboru Ando, Tomohiro Morio, Shozaburo Doi, Tetsushi FurukawaTokyo Medical and Dental University. Saitama Children’s Medical Center. National Hospital Organization Disaster Medical Center. Japan Journal of Pharmacology and Experimental TherapeuticsJ Pharmacol Exp Ther 2023; 385: 88-94DOI: 10.1124/jpet.122.001399 AbstractA pathogenic aspect of pulmonary arterial hypertension (PAH) is the aberrant pulmonary arterial smooth muscle cell

The Anti-Inflammatory Effects and Clinical Potential of Dexmedetomidine in Pulmonary Arterial Hypertension Read More »

Pharmacotherapy for Pulmonary Hypertension in Infants with Bronchopulmonary Dysplasia: Past, Present, and Future

Candice D. Fike, Judy L. AschnerUniversity of Utah Health. Joseph M. Sanzari Children’s Hospital at Hackensack University.United States PharmaceuticalsPharmaceuticals 2023; 16: DOI: 10.3390/ph16040503 AbstractApproximately 8-42% of premature infants with chronic lung disease of prematurity, bronchopulmonary dysplasia (BPD), develop pulmonary hypertension (PH). Infants with BPD-PH carry alarmingly high mortality rates of up to 47%. Effective PH-targeted pharmacotherapies

Pharmacotherapy for Pulmonary Hypertension in Infants with Bronchopulmonary Dysplasia: Past, Present, and Future Read More »